Holen Sie sich die Stockscreener-App
6.49
4.68%
0.29
Handel nachbörslich:
6.61
0.12
+1.85%
Schlusskurs vom Vortag:
$6.20
Offen:
$6.29
24-Stunden-Volumen:
2.02M
Relative Volume:
1.54
Marktkapitalisierung:
$563.31M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-168.09M
KGV:
-2.9908
EPS:
-2.17
Netto-Cashflow:
$-138.01M
1W Leistung:
+7.63%
1M Leistung:
+3.34%
6M Leistung:
-21.62%
1J Leistung:
-65.90%
1-Tages-Spanne:
$6.245
$6.735
1-Wochen-Bereich:
$5.45
$6.735
52-Wochen-Spanne:
$5.41
$21.57
Kura Oncology Inc Stock (KURA) Company Profile
Firmenname
Kura Oncology Inc
Sektor
Branche
Telefon
(858) 500-8800
Adresse
12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA
Vergleichen Sie KURA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
6.49 | 538.14M | 0 | -168.09M | -138.01M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-06 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-10-14 | Herabstufung | Stifel | Buy → Hold |
| 2023-12-22 | Eingeleitet | Mizuho | Buy |
| 2023-08-11 | Eingeleitet | BofA Securities | Buy |
| 2023-07-27 | Eingeleitet | Scotiabank | Sector Perform |
| 2023-05-17 | Eingeleitet | BTIG Research | Buy |
| 2023-01-31 | Eingeleitet | Stifel | Buy |
| 2022-07-12 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-02-15 | Eingeleitet | Jefferies | Buy |
| 2021-05-05 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-12-07 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-03 | Eingeleitet | Stifel | Buy |
| 2020-11-05 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Eingeleitet | Credit Suisse | Outperform |
| 2020-05-05 | Eingeleitet | Barclays | Overweight |
| 2019-07-18 | Eingeleitet | Deutsche Bank | Buy |
| 2018-11-09 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-08-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-10-13 | Fortgesetzt | Leerink Partners | Outperform |
| 2016-01-22 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2015-12-30 | Eingeleitet | Oppenheimer | Outperform |
| 2015-12-16 | Eingeleitet | Citigroup | Buy |
Alle ansehen
Kura Oncology Inc Aktie (KURA) Neueste Nachrichten
Analysts Weigh In on 10x Genomics, Kura Oncology and Insulet: Buy or Hold? - AInvest
Kura Oncology, Inc. (NASDAQ:KURA) Q2 2025 Earnings Call Transcript - Insider Monkey
Why Kura Oncology Inc. stock attracts strong analyst attentionDouble in 10 Days Stock Ideas - newsyoung.net
Kura Oncology’s SWOT analysis: ziftomenib’s potential drives stock outlook By Investing.com - Investing.com Nigeria
JMP Securities Maintains Market Outperform on Kura Oncology with New PT of $24 - AInvest
Kura Oncology stock price target lowered to $24 at Citizens JMP - Investing.com Canada
Kura Oncology price target lowered to $27 from $29 at BofA - TipRanks
Kura Oncology, Inc. (NASDAQ:KURA) Just Reported And Analysts Have Been Cutting Their Estimates - Yahoo Finance
Is Kura Oncology Inc. stock entering bullish territoryDividend Strategy Summary With 10-Year Outlook - Newser
What makes Kura Oncology Inc. stock price move sharplyFree Daily Chart Pattern Stock Forecast - Newser
How hedge fund analytics apply to Kura Oncology Inc. stockROI Focused Setup Screener With Exit Markers - Newser
Order flow analysis tools used on Kura Oncology Inc.Equity Performance Forecast Based on AI Models - Newser
Chart based analysis of Kura Oncology Inc. trendsFree Short Term Buy Zone Stock Alerts - Newser
Candlestick Reversal Detected on Kura Oncology Inc.’s ChartStrong Buy With Technical Confidence Supported - beatles.ru
How to escape a deep drawdown in Kura Oncology Inc.Market Downturn Defense Strategy Analysis - Newser
Kura Oncology shares fall 5.12% intraday despite FDA Priority Review of ziftomenib NDA. - AInvest
Kura Oncology’s Promising Future: Strong Financials and Advancements in AML Treatment Drive Buy Rating - TipRanks
Earnings call transcript: Kura Oncology Q2 2025 shows revenue miss, EPS below forecast - Investing.com
Kura Oncology Inc (KURA) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Rising Expenses By GuruFocus - Investing.com Canada
Kura Oncology Inc (KURA) Q2 2025 Earnings Call Highlights: Strat - GuruFocus
Kura Oncology Advances Cancer Drug Pipeline with FDA Review - TipRanks
Published on: 2025-08-07 23:14:29 - Newser
Kura Oncology: Strong Financials and Promising Clinical Developments Drive Buy Rating - TipRanks
Kura Oncology Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Kura Oncology (KURA) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Kura Oncology: Q2 Earnings Snapshot - San Antonio Express-News
Kura Oncology Reports Second Quarter 2025 Financial Results | KU - GuruFocus
Kura Oncology Inc earnings missed by $0.34, revenue fell short of estimates - Investing.com South Africa
Q2 2025 Kura Oncology Inc Earnings Call Transcript - GuruFocus
Kura Oncology Reports Second Quarter 2025 Financial Results - Yahoo Finance
Dimensional US Core Equity 2 ETF (DFAC) Implied Analyst Target Price: $41.37, With 12.92% Upside Expected. - AInvest
Kura Oncology Grants Inducement Stock Options to New Employees Under Nasdaq Listing Rule - AInvest
Kura Oncology KURA Q2 2025 Earnings Preview Upside Potential on Robust Revenue Forecast - AInvest
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rul - GuruFocus
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Kura Oncology grants stock options to new employees under inducement plan. - AInvest
Cancer Drug Developer Kura Oncology Makes Major Hiring Push: 35 New Scientists Join Precision Medicine Team - Stock Titan
How strong is Kura Oncology Inc. company’s balance sheetUnlock powerful investment tools for free - Jammu Links News
What are the technical indicators suggesting about Kura Oncology Inc.Unlock powerful trading signals and alerts - Jammu Links News
What markets is Kura Oncology Inc. expanding into Is GURE stock a good long term investment optionTremendous gains - Jammu Links News
What institutional investors are buying Kura Oncology Inc. stockTake advantage of unprecedented market momentum - Jammu Links News
What drives Kura Oncology Inc. stock priceUnmatched profit potential - Jammu Links News
What are analysts’ price targets for Kura Oncology Inc. in the next 12 monthsDiscover stocks with explosive upside potential - Jammu Links News
Why is Kura Oncology Inc. stock attracting strong analyst attentionMaximize returns with disciplined trading approaches - Jammu Links News
Using flow based indicators on Kura Oncology Inc.Asset Allocation Summary With Future Outlook - Newser
What are the latest earnings results for Kura Oncology Inc.Fast-track wealth growth - Jammu Links News
Kura Oncology targets 2028 MRD-negative CR results for frontline AML trials - MSN
Is Kura Oncology Inc. the Top Chart Pick This WeekOptimized Return Investment Picks - beatles.ru
How does Kura Oncology Inc. generate profit in a changing economyEntry Signal Report For Beginners - jammulinksnews.com
Kura Oncology Sets Q2 Earnings Date: Cancer Drug Pipeline Update Coming August 7 - Stock Titan
Kura Oncology to Report Second Quarter 2025 Financial Results - The Manila Times
Finanzdaten der Kura Oncology Inc-Aktie (KURA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):